BUELACH, Switzerland,

BIOTRONIK Announces Its Latest Innovation: Oscar Multifunctional Peripheral Catheter

Ground-Breaking New All-In-One Device is First to Offer a Combination of Adjustable Guidewire Support Strength and Length-Adjustable Angioplasty Balloon to Reach, Cross and Prepare PAD Lesions

BIOTRONIK announces the FDA 510(k) clearance and CE mark of its Oscar® (One Solution: Cross. Adjust. Restore) multifunctional peripheral catheter. Physicians in the U.S. have already used the novel device in more than 70 cases. As indicated per Instructions for Use, Oscar is intended for percutaneous transluminal interventions in the peripheral vasculature. The device was developed to provide support during access into and to dilate stenoses in femoral, popliteal and infrapopliteal arteries. 

The Oscar peripheral multifunctional catheter is comprised of three user-adjustable components:

  • Oscar support catheter with integrated Lock Grip
  • Oscar extendable dilator
  • Oscar length-adjustable percutaneous transluminal angioplasty (PTA) balloon

The Oscar system will be available in 11 total size configurations with either 0.014”/4F or 0.018”/6F guidewire/introducer sheath compatibility. This may massively reduce stock units required compared to a standard PTA balloon. Additional standalone Oscar PTA balloons are also available separately to be used with the Oscar support catheter.

The Oscar support catheter and dilator are used in tandem to enable lesion access and crossing with a compatible guidewire, offering a wide range of support strength, adjusted with the extension of the dilator. At its strongest support level, the combination provides up to 55% more pushability than the leading 0.035” support catheter.1 

Each Oscar multifunctional catheter configuration contains one length adjustable PTA balloon. The physician will simply select the configuration based on the desired balloon diameter. The PTA balloon’s length is adjustable from 20 to 180 mm, allowing users to customize angioplasty by matching the balloon exactly to the lesion length.2

The first procedure with the Oscar system in the U.S. was performed by Jihad A. Mustapha, MD, President & Chief Executive Officer and Director of Endovascular Interventions at Advanced Cardiac & Vascular Centers for Amputation Prevention Grand Rapids, Michigan, USA. “Oscar is a game-changing product. In cases where we had previously failed with multiple treatment approaches, the Oscar catheter made it possible to succeed, while also saving time and reducing how long the patient needs to spend on the table. This is one of the best support systems I’ve ever used, and the length-adjustable balloon functionality is exceptional,” stated Dr. Mustapha.

More than 70 cases have been performed in U.S. hospitals with the Oscar device as part of BIOTRONIK’s pre-launch evaluations. Despite highly complex disease, the Oscar catheter demonstrated a 90%1 crossing success rate and a PTA technical success rate of 95%1. In some cases, physicians had previously tried and failed with traditional crossing devices and strategies.

“We are thrilled to be leading a change in paradigm for peripheral interventions with the introduction of the Oscar multifunctional peripheral catheter. The new device has the potential to redefine the way physicians approach their complex PAD cases,” said Dr. Joerg Pochert, President Vascular Intervention at BIOTRONIK.

The product will be commercially available in the United States starting in the Spring of 2023 and in CE mark accepting regions in the second half of 2023.



For more information, please visit: Oscar Multifunctional Peripheral Catheter


1 BIOTRONIK data on file. Testing performed with Oscar 0.018/6F support catheter and dilator combination.

2 7 mm PTA balloon length range is 20 to 100 mm.

Oscar is a trademark or registered trademark of the BIOTRONIK Group of Companies.


At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.